2025-522812-18-00Not yet recruitingPhase 4
CARESS Study: Cabergoline for the Reduction of Endometriosis Symptoms and Lesion Size
Source: EU CTIS (euclinicaltrials.eu) · Last updated 17 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To evaluate the efficacy of cabergoline (0.5 mg twice weekly) in reducing the size of endometriotic lesions and alleviating pelvic pain in women with confirmed endometriosis, compared with a control group receiving standard treatment (dienogest or combined contraceptives) for endometriosis.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 20 Jun 2025
- Start date
- 1 Sept 2025
- Lead sponsor
- Hospital Clinico San Carlos
- Diseases
- Endometriosis
- EU CT number
- 2025-522812-18-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for premenopausal women aged 18 to 40 with confirmed endometriosis and pelvic pain. It tests cabergoline against standard treatment.
- Age
- 18 to 40 years old, and premenopausal. (The registry header lists 18 to 64 years.)
- Sex
- The record is unclear. The sex field says male, but the criteria and summary describe women with endometriosis.
- Disease stage
- Endometriosis confirmed by ultrasound, magnetic resonance imaging or laparoscopy. Pelvic pain for at least 1 month, with a VAS pain score of 3 points or more.
- Earlier treatment
- No treatment with cabergoline in the three months before the study.
Main reasons for not taking part
- Allergy to dopamine agonists, or serious side effects with cabergoline before
- Severe uncontrolled other illness (ASA above III)
- Active thromboembolic disease
- Pregnant or breastfeeding at the start
- Heart valve disorders, fibrotic disorders, impaired liver function, or breast cancer
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Documented allergy to dopamine agonists or previous serious side effects with cabergoline
Other illness
- Active thromboembolic disease.
- History of heart valve disorders, history of fibrotic disorders, or impaired liver function.
- Breast Cancer
Other
- Severe uncontrolled comorbidities (ASA> III).
- Pregnancy or breastfeeding at the start of the study.
- Patient unwillingness to participate in the study
Who the study is looking for
- Aged between 18 and 40 years old, and premenopausal.
- Confirmed diagnosis of endometriosis by ultrasound/magnetic resonance imaging/laparoscopy.
- Pelvic pain (≥1 month) assessed using a VAS scale ≥3 points.
- No treatment with cabergoline in the three months prior to the start of the study.
- BMI between 18 and 35 kg/m².
- No allergy to the treatments.
- Consent to participate in the study.
- Ability to speak and understand the message.
Age in the registry: 18 years to 64 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Clínico San Carlos | Madrid | Spain | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.